Bluebird bio price target cut; Fulcrum upgraded as Morgan Stanley shakes up SCD coverage
naphtalina/iStock via Getty Images
- After recent developments, Morgan Stanley analysts led by Matthew Harrison have reshuffled their ratings and price targets on the stocks focused on the market for sickle cell disease (SCD).
- Despite over twofold rise in…
